Novartis

Novartis

Web: ?c=930d6c14fe03e2bad7a08c0d48846716" target="_blank" rel="nofollow"> Novartis external link
Discipline: Medicine/Pharmacology
Related to:

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.
?c=930d6c14fe03e2bad7a08c0d48846716" target="_blank" rel="nofollow"> #display_name

Medicine Jun 18
Novartis International AG: Alcon AcrySof IQ PanOptix trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery Better visual outcomes for patients with the AcrySof IQ PanOptix intraocular lens at near and intermediate distance vision -   Detailed findings presented at World Ophthalmology Congress 201
Medicine Jun 16

Overall response rate was 52% and median duration of response was not reached at a median follow-up of 14 months, signifying responses were durable -   Patients had a 65% chance of being relapse-fr

Medicine Jun 15

Findings from more than 1,300 patients across 13 countries showed ITP had especially high impact for many patients on emotional well-being (36%) and ability to work (28%) About two-thirds of patien

Medicine Jun 7

Novartis announces JCO publication of Lutathera NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs Patients repor

Medicine Jun 1

Novartis AG ("Novartis") today announced the completion of the divestment to GlaxoSmithKline PLC ("GSK") of its 36.5 percent stake in a consumer healthcare joint venture (JV) for a total consideration of USD13.0 billion.

Medicine Jun 15

Novartis study of real-world data concludes Jakavi is associated with a reduction in risk of death and dangerous blood clots for patients with rare blood cancer Comparison of Jakavi (ruxolitinib) vs.

Medicine Jun 15

Zessly (infliximab) matched the reference medicine in terms of safety and efficacy at 54 weeks, even in patients who switched from the reference medicine to Zessly Switching from the reference medi

Medicine Jun 2

New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna remain in remission almost three years after stopping therapy ENESTop and ENESTfreedom data evaluate Treatm

Medicine Jun 1

If approved, Aimovig (erenumab) is expected to be the first and only available therapy designed specifically for migraine prevention in the EU Positive opinion based on robust data package demonstr



website preview

Link

Medicine and Life Sciences